[.
]
Action/Kinetics:
Closely resembles thymidine; inhibits thymidylic phosphorylase and specific DNA polymerases necessary for incorporation of thymidine into viral DNA. Trifluridine, instead of thymidine, is incorporated into viral DNA, resulting in faulty DNA and the ability to infect or reproduce in tissue. Also incorporated into mammalian DNA. Has activity against herpes simplex virus types 1 and 2 and vaccinia virus.
t
1/2: 12-18 min.
Uses:
Primary keratoconjunctivitis and recurrent epithelial keratitis caused by HSV types 1 and 2. Epithelial keratitis resistant to idoxuridine or if ocular toxicity or hypersensitivity to idoxuridine has occurred. Is also indicated for infections resistant to vidarabine.
Contraindications:
Hypersensitivity or chemical intolerance to drug.
Special Concerns:
Safe use during pregnancy not established. Use with caution during lactation.
Side Effects:
Ophthalmic: Mild, transient burning or stinging when instilled. Palpebal edema, superficial punctate keratopathy, epithelial keratopathy, hypersensitivity reaction, stomal edema, irritation, eratitis sicca, hyperemia, increased intraocular pressure.
How Supplied:
Ophthalmic Solution: 1%
Dosage
?Solution, 1%
1 gtt solution q 2 hr onto cornea, up to maximum of 9 gtt/day in each eye during acute stage (presence of corneal ulcer). Following reepithelialization, decrease dosage to 1 gtt/4 hr (or minimum of 5 gtt/day in each eye) for 7 days. Do not use for more than 21 days.
